NCT00873405

Brief Summary

Obesity is a multifactorial disease that affects millions of people worldwide. It is the main independent risk factor for developing type 2 diabetes mellitus (T2DM). Most patients with T2DM and glucose intolerance (GI) are overweight, a condition known as diabesity. In patients with the most severe form of obesity, i.e., morbid obesity, the likelihood of developing diseases associated with obesity is increased. The investigators currently know that bariatric surgery provides sustained weight loss and well-documented remission of T2DM. Patients who undergo bariatric surgery show long-term reduced mortality from coronary artery disease, cancer and diabetes; 136 lives are saved per 10,000 surgical procedures performed. Bariatric surgery is a relatively safe procedure that is becoming increasingly well-accepted; in 2007, approximately 170,000 bariatric procedures were performed in the USA. Currently, bariatric surgery is the most effective choice of treatment of morbidly obese patients with diabetes. The surgical procedures that are currently performed to treat morbid obesity are divided into two main groups: gastric restrictive procedures and combination procedures; the latter combine gastric restriction and malabsorption. The roux-en-Y gastric bypass (RYGB) is the combination procedure most frequently performed, whereas sleeve gastrectomy (SG) is an emerging restrictive procedure. SG can be performed as the first of a two-stage operation in patients at high risk of death, or as a definitive surgical procedure. It has shown good results with regard to weight loss and glycemic control in various studies. The potential advantages of SG include lower probability of vitamin and mineral deficiencies because this procedure has no malabsorptive component; access to the entire intestinal tract; no need for a subcutaneous access port or adjustments; absence of dumping syndrome and lower probability of intestinal obstruction. In addition, SG can be performed in patients who have inflammatory bowel disease or who have undergone bowel surgery, and it can be easily converted into RYGB. Both SG and RYGB can be performed with or without the placement of a Silastic® ring. The metabolic control achieved with bariatric procedures has been demonstrated and reproduced in various medical centers worldwide. Metabolic control can be achieved with gastric restrictive procedures such as vertical banded gastroplasty, adjustable gastric banding and, more recently, SG. However, it has been shown that glucose homeostasis is affected by various intestinal mechanisms observed exclusively in procedures that include a malabsorptive element, such as RYGB. A systematic review of 22,094 cases of morbidly obese patients submitted to bariatric surgery has shown that resolution of T2DM was achieved in 76.8% of the cases, improvement being achieved in 86% of cases. Among the criteria used to diagnose metabolic syndrome, fasting glucose levels are the first to return to normal in patients submitted to Silastic® ring gastric bypass (SRGB), a modification of the traditional RYGB which consists in adding a Silastic® ring to the gastric bypass operation. Normoglycemia after bariatric procedures, as well as diabesity itself, is multifactorial. Normoglycemia is observed as a result of dietary control, decreased plasma levels of ghrelin, weight loss and reduction of body fat, as well as of the release of gastrointestinal hormones that interfere with the function of pancreatic β cells (incretins). The main purpose of this study was to compare the weight loss of morbidly obese patients submitted to either a Silastic® ring sleeve gastrectomy (SRSG) or an SRGB, as well as to compare the effects of both procedures on glucose homeostasis in morbidly obese patients.

Trial Health

55
Monitor

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
65

participants targeted

Target at P50-P75 for not_applicable obesity

Geographic Reach
1 country

1 active site

Status
unknown

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

June 1, 2006

Completed
2.8 years until next milestone

First Submitted

Initial submission to the registry

March 31, 2009

Completed
1 day until next milestone

First Posted

Study publicly available on registry

April 1, 2009

Completed
2 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

June 1, 2009

Completed
Last Updated

April 1, 2009

Status Verified

March 1, 2009

Enrollment Period

3 years

First QC Date

March 31, 2009

Last Update Submit

March 31, 2009

Conditions

Keywords

Type 2 diabetes mellitusMetabolic controlBariatric SurgeryWeight LossSleeve gastrectomyBMI reductionWaist circumference reductionPercentage of excess BMI lossGlucose homeostasis

Outcome Measures

Primary Outcomes (1)

  • Weight loss, BMI reduction and waist circumference reduction

    12 months

Secondary Outcomes (1)

  • Glucose homeostasis, metabolic control.

    12 months

Study Arms (2)

SRSG

ACTIVE COMPARATOR

Silastic® ring sleeve gastrectomy (SRSG).

Procedure: Silastic® ring sleeve gastrectomy

SRGB

OTHER

Silastic® ring gastric bypass.

Procedure: Silastic® ring sleeve gastrectomyProcedure: Silastic® ring gastric bypass

Interventions

SRSG group: ligation of the vessels of the greater curvature of the body and fundus of stomach; resection of the fundus and part of the body of stomach using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the remaining stomach; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.

Also known as: Sleeve gastrectomy
SRGBSRSG

SRGB group: creation of a small, proximal gastric pouch using a linear stapler (80 mm, Tyco®) and a 32-Fr tube to calibrate the gastric pouch; creation of an intestinal loop of 150 cm and a biliopancreatic loop of 40 cm; placement of a 6.2 cm Silastic® ring around the stomach, 5.0 cm below the esophagogastric junction.

Also known as: gastric bypass
SRGB

Eligibility Criteria

Age20 Years - 60 Years
Sexfemale
Healthy VolunteersNo
Age GroupsAdult (18-64)

You may qualify if:

  • female patients aged 20-60 years
  • BMI 40-45 (inclusive)
  • agreed on giving written informed consent

You may not qualify if:

  • secondary obesity
  • alcohol or drug use
  • severe psychiatric disorder
  • binge-eating of sweets
  • previous stomach or bowel surgery

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Cassiano Antonio Moraes University Hospital, Federal University of Espírito Santo

Vitória, Espírito Santo, 29040-091, Brazil

Location

Related Publications (19)

  • Lee CM, Cirangle PT, Jossart GH. Vertical gastrectomy for morbid obesity in 216 patients: report of two-year results. Surg Endosc. 2007 Oct;21(10):1810-6. doi: 10.1007/s00464-007-9276-y. Epub 2007 Mar 14.

    PMID: 17356932BACKGROUND
  • Cottam D, Qureshi FG, Mattar SG, Sharma S, Holover S, Bonanomi G, Ramanathan R, Schauer P. Laparoscopic sleeve gastrectomy as an initial weight-loss procedure for high-risk patients with morbid obesity. Surg Endosc. 2006 Jun;20(6):859-63. doi: 10.1007/s00464-005-0134-5. Epub 2006 Apr 22.

    PMID: 16738970BACKGROUND
  • Silecchia G, Boru C, Pecchia A, Rizzello M, Casella G, Leonetti F, Basso N. Effectiveness of laparoscopic sleeve gastrectomy (first stage of biliopancreatic diversion with duodenal switch) on co-morbidities in super-obese high-risk patients. Obes Surg. 2006 Sep;16(9):1138-44. doi: 10.1381/096089206778392275.

    PMID: 16989696BACKGROUND
  • Baltasar A, Serra C, Perez N, Bou R, Bengochea M, Ferri L. Laparoscopic sleeve gastrectomy: a multi-purpose bariatric operation. Obes Surg. 2005 Sep;15(8):1124-8. doi: 10.1381/0960892055002248.

    PMID: 16197783BACKGROUND
  • Moon Han S, Kim WW, Oh JH. Results of laparoscopic sleeve gastrectomy (LSG) at 1 year in morbidly obese Korean patients. Obes Surg. 2005 Nov-Dec;15(10):1469-75. doi: 10.1381/096089205774859227.

    PMID: 16354529BACKGROUND
  • Vidal J, Ibarzabal A, Romero F, Delgado S, Momblan D, Flores L, Lacy A. Type 2 diabetes mellitus and the metabolic syndrome following sleeve gastrectomy in severely obese subjects. Obes Surg. 2008 Sep;18(9):1077-82. doi: 10.1007/s11695-008-9547-2. Epub 2008 Jun 3.

    PMID: 18521701BACKGROUND
  • Fobi M. Why the Operation I Prefer is Silastic Ring Vertical Gastric Bypass. Obes Surg. 1991 Dec;1(4):423-426. doi: 10.1381/096089291765560854.

    PMID: 10775946BACKGROUND
  • Buchwald H, Buchwald JN. Evolution of operative procedures for the management of morbid obesity 1950-2000. Obes Surg. 2002 Oct;12(5):705-17. doi: 10.1381/096089202321019747.

    PMID: 12448398BACKGROUND
  • Adams TD, Gress RE, Smith SC, Halverson RC, Simper SC, Rosamond WD, Lamonte MJ, Stroup AM, Hunt SC. Long-term mortality after gastric bypass surgery. N Engl J Med. 2007 Aug 23;357(8):753-61. doi: 10.1056/NEJMoa066603.

    PMID: 17715409BACKGROUND
  • Sjostrom L, Narbro K, Sjostrom CD, Karason K, Larsson B, Wedel H, Lystig T, Sullivan M, Bouchard C, Carlsson B, Bengtsson C, Dahlgren S, Gummesson A, Jacobson P, Karlsson J, Lindroos AK, Lonroth H, Naslund I, Olbers T, Stenlof K, Torgerson J, Agren G, Carlsson LM; Swedish Obese Subjects Study. Effects of bariatric surgery on mortality in Swedish obese subjects. N Engl J Med. 2007 Aug 23;357(8):741-52. doi: 10.1056/NEJMoa066254.

    PMID: 17715408BACKGROUND
  • Must A, Spadano J, Coakley EH, Field AE, Colditz G, Dietz WH. The disease burden associated with overweight and obesity. JAMA. 1999 Oct 27;282(16):1523-9. doi: 10.1001/jama.282.16.1523.

    PMID: 10546691BACKGROUND
  • Cummings DE, Overduin J, Foster-Schubert KE. Gastric bypass for obesity: mechanisms of weight loss and diabetes resolution. J Clin Endocrinol Metab. 2004 Jun;89(6):2608-15. doi: 10.1210/jc.2004-0433. No abstract available.

    PMID: 15181031BACKGROUND
  • Buchwald H, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. JAMA. 2004 Oct 13;292(14):1724-37. doi: 10.1001/jama.292.14.1724.

    PMID: 15479938BACKGROUND
  • Langer FB, Reza Hoda MA, Bohdjalian A, Felberbauer FX, Zacherl J, Wenzl E, Schindler K, Luger A, Ludvik B, Prager G. Sleeve gastrectomy and gastric banding: effects on plasma ghrelin levels. Obes Surg. 2005 Aug;15(7):1024-9. doi: 10.1381/0960892054621125.

    PMID: 16105401BACKGROUND
  • Nakazato M, Murakami N, Date Y, Kojima M, Matsuo H, Kangawa K, Matsukura S. A role for ghrelin in the central regulation of feeding. Nature. 2001 Jan 11;409(6817):194-8. doi: 10.1038/35051587.

    PMID: 11196643BACKGROUND
  • Pories WJ, Albrecht RJ. Etiology of type II diabetes mellitus: role of the foregut. World J Surg. 2001 Apr;25(4):527-31. doi: 10.1007/s002680020348. Epub 2001 Apr 18.

    PMID: 11344408BACKGROUND
  • Cai J, Zheng C, Xu L, Chen D, Li X, Wu J, Li J, Yin K, Ke Z. Therapeutic effects of sleeve gastrectomy plus gastric remnant banding on weight reduction and gastric dilatation: an animal study. Obes Surg. 2008 Nov;18(11):1411-7. doi: 10.1007/s11695-008-9490-2. Epub 2008 Apr 26.

    PMID: 18438617BACKGROUND
  • Braghetto I, Korn O, Valladares H, Gutierrez L, Csendes A, Debandi A, Castillo J, Rodriguez A, Burgos AM, Brunet L. Laparoscopic sleeve gastrectomy: surgical technique, indications and clinical results. Obes Surg. 2007 Nov;17(11):1442-50. doi: 10.1007/s11695-008-9421-2.

    PMID: 18219770BACKGROUND
  • Deitel M, Gawdat K, Melissas J. Reporting weight loss 2007. Obes Surg. 2007 May;17(5):565-8. doi: 10.1007/s11695-007-9116-0. No abstract available.

    PMID: 17658011BACKGROUND

MeSH Terms

Conditions

ObesityDiabetes Mellitus, Type 2Weight Loss

Interventions

Gastric Bypass

Condition Hierarchy (Ancestors)

OverweightOvernutritionNutrition DisordersNutritional and Metabolic DiseasesBody WeightSigns and SymptomsPathological Conditions, Signs and SymptomsDiabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesEndocrine System DiseasesBody Weight Changes

Intervention Hierarchy (Ancestors)

Bariatric SurgeryBariatricsObesity ManagementTherapeuticsGastroenterostomyAnastomosis, SurgicalSurgical Procedures, OperativeDigestive System Surgical Procedures

Study Officials

  • Gustavo PS Miguel, Surgery Assistant Professor

    Federal University of Espírito Santo

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
NON RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER

Study Record Dates

First Submitted

March 31, 2009

First Posted

April 1, 2009

Study Start

June 1, 2006

Primary Completion

June 1, 2009

Last Updated

April 1, 2009

Record last verified: 2009-03

Locations